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Focal segmental glomerulosclerosis (FSGS) is one of the pri-
mary glomerular disorders in both children and adults which
canprogress to end-stage renal failure. Recent advances in cell
biology and genetics have found newmolecules and signaling
mechanisms in podocytes for the pathogenesis of FSGS. In
addition, evidence-based approaches will guide to the best
and appropriate therapeutic options both in children and in
adults with FSGS in this special issue.
The exact steps in the etiopathogenesis of FSGS are
incompletely understood. In an attempt to summarize find-
ings related to the immunologic changes, A. Kronbichler
et al. provide an overview of T-cell, CD80 (B7-1), comple-
ment, chemokines/cytokines, macrophages, and B-cells in
FSGS. Moreover, the authors highlight a potential transition
into current and future potential therapeutic options. E.
Ko¨nigshausen and L. Sellin reviewed potential circulating
permeability factors in primary FSGS that have been impli-
cated in the pathogenesis due to the potential recurrence in
renal allografts after kidney transplantation (KT), focusing
on the soluble urokinase plasminogen activator receptor
(suPAR), cardiotrophin-like cytokine factor-1 (CLCF-1), and
CD40 antibodies. Secondary FSGS is an emerging cause
of progressive kidney function decline. With the increased
understanding of podocyte biology, several steps have been
identified leading to podocyte injury and eventually glomeru-
losclerosis. In an elegant overview, J. S. Kim et al. provide
an overview of common causes leading to secondary FSGS,
including adaptive (with reduced or normal renal mass),
drug-induced, genetic, or infection-related disease forms.
Regarding pathologic classifications of FSGS, M.-H. Han
and Y.-J. Kim reviewed the Columbia classification, which
distinguishes five variants (collapsing, tip, cellular, perihilar,
and not otherwise specified) and has been widely used over
the past 10 years, and pointed out the confusion about
terminology of variants and difficulty in its application and
the interpretation of lesions with mixed features in the same
tissue specimen or evolution of the lesions. For the diagnosis
of FSGS, B. Sprangers et al. reviewed on the diagnostic
approaches and work-up to the patients using the potential
biomarkers of FSGS, genetic testing, and histology.
Treatment of primary FSGS remains a challenge for the
treating physicians, since repeated doses of long-term steroid
use and steroid-dependence and steroid-resistance are lead-
ing to significant morbidities in both children and adults.
K. H. Han and S. H. Kim reviewed on the current updated
strategies for treatment of primary FSGS in children, includ-
ing traditional therapies consisting of corticosteroids and
calcineurin inhibitors and novel therapies such as rituximab,
abatacept, adalimumab, and fresolimumab. A. Beer et al.
focused on studies reporting on treatment outcomepublished
during the last two decades. Unfortunately, there has not been
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a major progress in the treatment of adults and novel sub-
stances, such as sirolimus; adalimumab or galactose should
not be considered as effective immunosuppressive mea-
sures. While rituximab, mycophenolate mofetil, or calcineu-
rin inhibitors may be used in steroid-dependence, evi-
dence is limited for the former two substances in resistant
cases and other strategies such as extracorporeal treatment
(immunoadsorption or plasma exchange) and alkylating
agents may be used.
FSGS is known to recur after KT and is an important
cause of graft loss early after transplantation. H. G. Kang et al.
reviewed on the risk factors of FSGS recurrence after KT
in children, potential biomarkers for predicting recurrence,
treatment of FSGS recurrence after KT, and the strategies to
prevent recurrences. M. Rudnicki reviewed on FSGS recur-
rence in adults after KT, emphasizing prophylactic and peri-
operative treatment with plasmapheresis and high-dose (int-
ravenous) cyclosporine as themain cornerstones of immuno-
suppressive therapy and recent promising results of rituximab
therapy.
Articles published in this special issue covered the various
fields of FSGS such as pathophysiologic mechanisms of pri-
mary and secondary FSGS, histopathologic considerations,
potential biomarkers and diagnostic work-up, evidence-
based therapeutic strategies, and recurrence of FSGS after KT.
Understanding theses various faces of FSGSwill lead to better
patient treatment and outcome.
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